Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 25 of 27 entries
View as:

Comparative Study of Clinical Efficacy and Safety of GNR-069 and Nplate in Patients With ITP

Phase: N/A Priority: Normal
NCT ID: NCT05220878 Org: User:
Start: 09/09/21 End: 10/19/23 Due: 10/19/24

A Multi-cohort Study of the Tolerance, Safety, and Pharmacokinetics of GNR-055 in Healthy Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT04539340 Org: User:
Start: 02/28/20 End: 09/08/20 Due: 09/08/21

A Study of Genolair in Two Dosage Forms (Solution and Lyophilisate) and Xolair® in Healthy Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT06494345 Org: User:
Start: 01/15/23 End: 06/09/24 Due: 06/09/25

GNR-084 Safety and Pharmacological Characteristics in Refractory or Relapse B-cell Precursor ALL

Phase: N/A Priority: Normal
NCT ID: NCT04601584 Org: User:
Start: 10/15/20 End: 06/30/25 Due: 06/30/26

Study of Efficacy and Safety of GNR-060 vs Metalyse in Patients With ST Elevation Myocardial Infarction

Phase: N/A Priority: Normal
NCT ID: NCT05601999 Org: User:
Start: 09/03/21 End: 10/31/24 Due: 10/31/25

Efficacy, Safety, pharmacokinetiсs, Immunogenicity of GNR-067 and Lucentis®

Phase: N/A Priority: Normal
NCT ID: NCT04667039 Org: User:
Start: 03/20/22 End: 09/15/24 Due: 09/15/25

Observational Study of Elizaria® in aHUS Patients

Phase: N/A Priority: Normal
NCT ID: NCT04749810 Org: User:
Start: 12/19/19 End: 04/30/22 Due: 04/30/23

Prospective Observational Study of Long-term Pathogenic Treatment of Elizaria®

Phase: N/A Priority: Normal
NCT ID: NCT04671810 Org: User:
Start: 06/13/19 End: 05/05/23 Due: 05/05/24

A Safety and Pharmacokinetic Study of Complarate (Tocilizumab Biosimilar) and Actemra® in Healthy Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT06481202 Org: User:
Start: 04/11/22 End: 08/19/22 Due: 08/19/23

An Efficacy and Safety Study of GNR-068 (Ustekinumab Biosimilar) and Stelara® in the Treatment of Patients With Moderate to Severe Plaque Psoriasis

Phase: N/A Priority: Normal
NCT ID: NCT06488664 Org: User:
Start: 07/25/23 End: 03/20/25 Due: 03/20/26

An Efficacy and Safety Study of Genolar® and Xolar® in the Persistent Atopic Bronchial Asthma

Phase: N/A Priority: Normal
NCT ID: NCT04607629 Org: User:
Start: 06/20/18 End: 12/13/19 Due: 12/13/20

A Study of the Tolerance, Safety, and Pharmacokinetics of GNR-055 in Healthy Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT06475404 Org: User:
Start: 04/06/23 End: 09/20/23 Due: 09/20/24

A Safety and Pharmacokinetics Study of Ustekinumab Biosimilar GNR-068 and Stelara® in Healthy Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT06481215 Org: User:
Start: 03/11/22 End: 12/20/22 Due: 12/20/23

Efficacy and Safety of Tigerase® vs. Pulmozyme® in Patients With Cystic Fibrosis

Phase: N/A Priority: Normal
NCT ID: NCT04468100 Org: User:
Start: 08/30/17 End: 05/16/18 Due: 05/16/19

A Safety, Pharmacokinetics and Pharmacodynamics Study of GNR-086 and Ilaris® in Healthy Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT06481189 Org: User:
Start: 09/06/22 End: 05/26/23 Due: 05/26/24

Study of Pharmacokinetics, Pharmacodynamics and Safety Assessment of GNR-044 (JSC GENERIUM, Russia) and Xolair®

Phase: N/A Priority: Normal
NCT ID: NCT04601389 Org: User:
Start: 04/18/17 End: 09/06/17 Due: 09/06/18

A Safety and Immunogenicity Study in Long-term Treatment of Eculizumab (JSC "GENERIUM", Russian Federation)

Phase: N/A Priority: Normal
NCT ID: NCT04679103 Org: User:
Start: 05/03/18 End: 04/20/20 Due: 04/20/21

Study of the Safety and Immunogenicity of Long-term GNR-069 Therapy in ITP Patients

Phase: N/A Priority: Normal
NCT ID: NCT05492409 Org: User:
Start: 03/28/22 End: 04/03/24 Due: 04/03/25

A Safety and Pharmacokinetics Study of Complarate (Tocilizumab Biosimilar Solution) and Actemra® in Healthy Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT06488521 Org: User:
Start: 06/20/24 End: 12/12/24 Due: 12/12/25

A Multi-cohort Study of Safety, Efficacy, PK and PD of GNR-055 in Patients With Mucopolysaccharidosis Type II

Phase: N/A Priority: Normal
NCT ID: NCT05208281 Org: User:
Start: 11/30/21 End: 03/31/28 Due: 03/31/29

An Efficacy and Safety Study of GNR-086 (canakinumab Biosimilar) and Ilaris® in Patients with Adult-onset Still's Disease

Phase: N/A Priority: Normal
NCT ID: NCT06497491 Org: User:
Start: 12/12/23 End: 12/31/25 Due: 12/31/26

Comparison of Complarate® (Tocilizumab Biosimilar) and Actemra® in Patients With Rheumatoid Arthritis

Phase: N/A Priority: Normal
NCT ID: NCT06475508 Org: User:
Start: 02/13/23 End: 06/11/24 Due: 06/11/25

A Phase 1 Study of GNR-051 in Subjects With Advanced Malignancies

Phase: N/A Priority: Normal
NCT ID: NCT04544748 Org: User:
Start: 07/22/20 End: 01/31/25 Due: 01/31/26

Tigerase® Efficacy and Safety as Part of Complex Therapy in Patients With COVID-19

Phase: N/A Priority: Normal
NCT ID: NCT04459325 Org: User:
Start: 06/01/20 End: 07/20/20 Due: 07/20/21

Efficacy and Safety of Elizaria® vs. Soliris® in Patients With PNH

Phase: N/A Priority: Normal
NCT ID: NCT04463056 Org: User:
Start: 11/29/17 End: 10/16/18 Due: 10/16/19